Karamata V V, Gandhi A M, Patel P P, Sutaria A, Desai M K
Department of Pharmacology, B.J. Medical College, Ahmedabad, Gujarat, India.
Department of Skin and Venereal Disease, B.J. Medical College, Ahmedabad, Gujarat, India.
Indian J Pharmacol. 2017 Jan-Feb;49(1):84-88. doi: 10.4103/ijp.IJP_166_16.
To study the use of drugs in patients suffering from psoriasis and their effect on quality of life (QOL).
This was a prospective, observational study carried out in newly diagnosed patient of psoriasis at Department of Pharmacology and Outpatient Department of Skin and Venereal diseases at tertiary care teaching hospital, and patients were divided into three groups: Group A: topical therapy alone, Group B: methotrexate with topical therapy, and Group C: cyclosporine with topical therapy. The efficacy of drug was measured using Psoriasis Area Severity Index (PASI). QOL was measured using Psoriasis Disability Index. Patients were followed up at 1 month and 6 months of treatment. Statistical analysis was done using analysis of variance (ANOVA) test.
A total 126 patients were enrolled, out of which 114 patients completed the study. PASI score was reduced significantly ( < 0.001) in each treatment group and QOL score was significantly ( < 0.001) decrease in Group B and C as compared to baseline at the end of 6 months. A significant ( < 0.001) reduction in PASI score and QOL was observed in patients of Group B and C as compared to Group A. Correlation between efficacy and QOL was not significant in all three treatment groups.
Combination therapy (topical + systemic) is more efficacious and associated with significant improvement of QOL as compared to topical therapy alone. Methotrexate and cyclosporine are equally efficacious in treating and improving the QOL in patients suffering from psoriasis.
研究银屑病患者的用药情况及其对生活质量（QOL）的影响。
这是一项前瞻性观察性研究，在一家三级护理教学医院的药理学系以及皮肤性病门诊对新诊断的银屑病患者进行。患者被分为三组：A组：仅外用治疗；B组：甲氨蝶呤联合外用治疗；C组：环孢素联合外用治疗。使用银屑病面积和严重程度指数（PASI）来衡量药物疗效。使用银屑病残疾指数来衡量生活质量。在治疗1个月和6个月时对患者进行随访。采用方差分析（ANOVA）进行统计分析。
共纳入126例患者，其中114例患者完成了研究。在6个月末，每个治疗组的PASI评分均显著降低（<0.001），与基线相比，B组和C组的生活质量评分显著降低（<0.001）。与A组相比，B组和C组患者的PASI评分和生活质量显著降低（<0.001）。在所有三个治疗组中，疗效与生活质量之间的相关性均不显著。
与单纯外用治疗相比，联合治疗（外用+全身用药）更有效，且与生活质量的显著改善相关。甲氨蝶呤和环孢素在治疗银屑病患者和改善其生活质量方面同样有效。
